Indian biotechnology company Intas Biopharmaceuticals (IBPL, Ahmedabad, Gujarat) has signed a memorandum of understanding (MoU) with the government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs).
Indian biotechnology company Intas Biopharmaceuticals (IBPL, Ahmedabad, Gujarat) has signed a memorandum of understanding (MoU) with the government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs).
The facility, dedicated for MAbs, will undertake large-scale manufacturing of the recombinant product with a capacity of 5,000 L in phases. The government of Gujarat will help the company obtain incentives under various schemes announced by the state and central government.
IBPL is already manufacturing and marketing biosimilars including GCSF, Interferon, Erythropoietin, and PEG-GCSF. The commercial production at the proposed MAbs facility is likely to commence by 2011.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.